1191044-58-2
中文名称 | 1191044-58-2 |
---|---|
中文同义词 | 化合物 T11477 |
英文名称 | GSK1059865 |
英文同义词 | GSK1059865;GSK-1059865 (GSK 1059865;Methanone, [(2S,5S)-2-[[(5-bromo-2-pyridinyl)amino]methyl]-5-methyl-1-piperidinyl](3-fluoro-2-methoxyphenyl)-;GSK1059865 HCl |
CAS号 | 1191044-58-2 |
分子式 | C20H23BrFN3O2 |
分子量 | 436.32 |
EINECS号 | |
相关类别 | |
Mol文件 | 1191044-58-2.mol |
结构式 | ![]() |
1191044-58-2 性质
沸点 | 575.8±50.0 °C(Predicted) |
---|---|
密度 | 1.376±0.06 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 二甲基亚砜:≥ 50 mg/mL(114.59 mM) |
形态 | 固体 |
酸度系数(pKa) | 4.89±0.10(Predicted) |
颜色 | 白色至米白色 |
Orexin 1 receptor
Treatment with GSK1059865 significantly decreases ethanol drinking in a dose-dependent manner in CIE-exposed mice. In contrast GSK1059865 decreases drinking in air-exposed mice only at the highest dose used. There is no effect of GSK1059865 on sucrose intake. GSK1059865 (0.3 nM-10 nM) produces non-surmountable antagonism with a dose-dependent rightward shift of the OXA EC 50 and a concomitant decrease of the agonist maximal response. The calculated pK B value is 8.77±0.12 for GSK1059865. GSK1059865 (0.1-3.3 μM) produces a classical surmountable profile with parallel rightward shift of the OXA EC 50 without depression of the agonist maximal response. Intraperitoneal administration of GSK1059865 produces a region-dependent inhibition of yohimbine-induced relative cerebral blood volume response. The administration of GSK1059865 per se produces a weak relative cerebral blood volume increase in several brain regions. GSK1059865-pretreated animals exhibit slightly higher baseline mean arterial blood pressure values than controls.
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/04/30 | HY-101534 | 1191044-58-2 GSK1059865 | 1191044-58-2 | 5mg | 1950元 |
2024/04/30 | HY-101534 | 1191044-58-2 GSK1059865 | 1191044-58-2 | 10mM * 1mLin DMSO | 2150元 |